100 related articles for article (PubMed ID: 17428537)
1. Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic leukemia.
Liu W; Zhu YS; Guo M; Yu Y; Chen GQ
Leuk Res; 2007 Nov; 31(11):1565-74. PubMed ID: 17428537
[TBL] [Abstract][Full Text] [Related]
2. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms.
Song MG; Gao SM; Du KM; Xu M; Yu Y; Zhou YH; Wang Q; Chen Z; Zhu YS; Chen GQ
Blood; 2005 May; 105(9):3714-21. PubMed ID: 15671440
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of beta-actin by protein kinase C-delta in camptothecin analog-induced leukemic cell apoptosis.
Wang S; Zheng Y; Yu Y; Xia L; Chen GQ; Yang YZ; Wang LS
Acta Pharmacol Sin; 2008 Jan; 29(1):135-42. PubMed ID: 18158875
[TBL] [Abstract][Full Text] [Related]
4. Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells.
Yu Y; Wang LS; Shen SM; Xia L; Zhang L; Zhu YS; Chen GQ
J Proteome Res; 2007 Sep; 6(9):3808-18. PubMed ID: 17655343
[TBL] [Abstract][Full Text] [Related]
5. NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.
Zhang N; Zhang H; Xia L; Zheng Y; Yu Y; Zhu Y; Chen G; Di W
Cancer Lett; 2009 Jun; 278(2):139-144. PubMed ID: 19339107
[TBL] [Abstract][Full Text] [Related]
6. Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway.
Zhao XY; He ZW; Wu D; Xu RZ
Chin Med J (Engl); 2007 May; 120(9):802-6. PubMed ID: 17531122
[TBL] [Abstract][Full Text] [Related]
7. A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia.
Iversen PO; Sørensen DR; Tronstad KJ; Gudbrandsen OA; Rustan AC; Berge RK; Drevon CA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3525-31. PubMed ID: 16740779
[TBL] [Abstract][Full Text] [Related]
8. NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.
Zheng Y; Wang LS; Xia L; Han YH; Liao SH; Wang XL; Cheng JK; Chen GQ
Proteomics; 2009 Apr; 9(8):2064-75. PubMed ID: 19322780
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
10. Evidence of functional interaction between NuMA-RARalpha and RXRalpha in an in vivo model of acute promyelocytic leukemia.
Sukhai MA; Thomas M; Xuan Y; Chan LS; Hamadanizadeh SA; Zhang T; Bharadwaj RR; Schuh AC; Wells RA; Kamel-Reid S
Oncogene; 2008 Aug; 27(34):4666-77. PubMed ID: 18408763
[TBL] [Abstract][Full Text] [Related]
11. CDA-II, a urinary preparation, induces growth arrest and apoptosis of human leukemia cells through inactivation of nuclear factor-kappaB in a caspase-dependent manner.
Huang J; Yang M; Liu H; Jin J
Food Chem Toxicol; 2009 Jan; 47(1):40-9. PubMed ID: 18761050
[TBL] [Abstract][Full Text] [Related]
12. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
13. Acute promyelocytic leukemia: from treatment to genetics and back.
Kogan SC; Bishop JM
Oncogene; 1999 Sep; 18(38):5261-7. PubMed ID: 10498878
[No Abstract] [Full Text] [Related]
14. Growth inhibitory effect of the somatostatin structural derivative (TT-232) on leukemia models.
Tejeda M; Gaál D; Csuka O; Kéri G
Anticancer Res; 2005; 25(1A):325-30. PubMed ID: 15816555
[TBL] [Abstract][Full Text] [Related]
15. The expanding role of arsenic in acute promyelocytic leukemia.
Tallman MS
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
[TBL] [Abstract][Full Text] [Related]
16. Platelet functions and clinical effects in acute myelogenous leukemia.
Foss B; Bruserud O
Thromb Haemost; 2008 Jan; 99(1):27-37. PubMed ID: 18217131
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
18. A novel camptothecin analog with enhanced antitumor activity.
Yount G; Yang Y; Wong B; Wang HJ; Yang LX
Anticancer Res; 2007; 27(5A):3173-8. PubMed ID: 17970058
[TBL] [Abstract][Full Text] [Related]
19. PU.1, a novel caspase-3 substrate, partially contributes to chemotherapeutic agents-induced apoptosis in leukemic cells.
Zhao M; Duan XF; Wen DH; Chen GQ
Biochem Biophys Res Commun; 2009 May; 382(3):508-13. PubMed ID: 19281794
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
